Systemic lupus erythematosus (SLE) has not had a novel treatment approved since GlaxoSmithKline PLC's B-lymphocyte stimulator (BlyS) inhibitor Benlysta (belimumab) gained approval, now a Chinese company is waiting for a green light for its novel lupus treatment.
Remegen Ltd. expects its novel dual inhibitor of BLyS and a proliferation-inducing ligand (APRIL) for lupus, an autoimmune condition prevalent...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

